Riskpilot← Back to searchSign inGet full accessWingfirm Pharma AB
ABActiveOrg 5568054208Wholesale of other food · NACE 4638Est. 20100 employees
Revenue 2024
SEK 0
EBITDA margin
—
0% vs 2023
Equity ratio
98.5%
Financial strength
Net profit 2024
SEK -8K
-122% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -8K | +0% |
| Net profit | SEK -8K | -122% |
| Total assets | SEK 341K | -6% |
| Equity | SEK 336K | -3% |
| Employees | 0 | — |
Legal name
Wingfirm Pharma AB
Org number
5568054208
Legal form
Aktiebolag
NACE code
4638 · Wholesale of other food
Founded
16 april 2010
Share capital
SEK 125 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Föremålet för bolagets verksamhet är att utveckla, importera, försälja och distribuera hälsokost-, hygien-, hudvårdsprodukter, naturläkemedel samt övriga produkter relaterade till hälso- och friskvård samt idka därmed förenlig verksamhet.
Address
Phone
+4686629442
Email
thilde@8511.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −1 | −22 | −30 | −8 | −8 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −1 | −22 | −30 | −8 | −8 |
| Net financials | −1 | 481 | — | 44 | — |
| Profit before tax | −2 | 459 | −30 | 36 | −8 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −2 | 459 | −30 | 36 | −8 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 486 | 348 | 317 | 361 | 341 |
| Equity | 365 | 338 | 309 | 345 | 336 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 120 | 10 | 8 | 16 | 5 |
| Total debt | 120 | 10 | 8 | 16 | 5 |
EBITDA margin
-800000.0%
This company
15.8%
Market median
-5063391% vs market
20202024
Equity ratio
98.5%
This company
38.2%
Market median
+158% vs market
20202024
Return on equity
-2.4%
This company
18.4%
Market median
-113% vs market
20202024
Net profit margin
-800000.0%
This company
8.1%
Market median
-9876643% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TO Authorized Recipient of Service | Authorized Recipient of Service | 2022 |
| Former (2) | ||
KT Authorized Recipient of Service | Authorized Recipient of Service | 2020 – 2021 |
UC Chief Auditor | Chief Auditor | 2020 – 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2020 | |
| Former (1) | ||
| Board of Directors | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Wingfirm Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl-Axel Torbjörn Andersson | Authorized Recipient of Service | 0 companies |
| Ulf Christian Borg | Chief Auditor | 0 companies |
| Thilde Omjit Nyvik | Authorized Recipient of Service | 0 companies |
| Vegard Moltubakk | Board of Directors | 0 companies |
| Evan Hansen | Deputy Board Member | 0 companies |
| Vivian Zahl | Board of Directors | 0 companies |